Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 1 (live, attenuated) ; poliovirus type 2 (live, attenuated) ; poliovirus type 3 (live, attenuated) - oral suspension - poliomyelitis virus - poliomyelitis oral, trivalent, live attenuated

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 2 (live, attenuated) ; poliovirus type 3 (live, attenuated) ; poliovirus type 1 (live, attenuated) - oral suspension - poliomyelitis virus - poliomyelitis oral, trivalent, live attenuated

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

glaxosmithkline pharmaceutical kenya limited, kenya - poliomyelitis virus - suspension, oral - >=10 ccid50/dose

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - heliotrope 6x, 8x, 12x, 30x - temporarily relieves negativity, lack of compassion, mental exhaustion, carelessness, or lack of fortitude.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Kenya - English - Pharmacy and Poisons Board

bilthoven biologicals b.v antonie van leeuwenhoeklaan 9-13, bilthoven, 3721 - inactivated poliomyelitis virus type 1… - suspension for injection - inactivated poliomyelitis virus type 1 -40… - viral vaccines: poliomyelitis vaccines

Uganda - English - National Drug Authority

serum institute of india pvt ltd - polio virus (sabin) - oral liquid ordinary liquids - type - i ?106.0 ccid50 type - iii ?105.8 ccid50

Israel - English - Ministry of Health

medison pharma ltd - defibrotide - concentrate for solution for infusion - defibrotide 80 mg / 1 ml - defibrotide - defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (vod) also known as sinusoidal obstructive syndrome (sos) in haematopoietic stem-cell transplantation (hsct) therapy.it is indicated in adults and in adolescents, children and infants over 1 month of age .

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef 1); polio virus type 3 32 dagu (saukett) - suspension for injection - 40dagu/8dagu/32dagu - active: polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef 1) polio virus type 3 32 dagu (saukett) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 40 dagu; polio virus type 2 8 dagu; polio virus type 3 32 dagu - solution for injection - active: polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu excipient: albumin formaldehyde phenoxyethanol

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.